A Phase 1,Open -Label Study to Assess the Absorption, Metabolism and Excretion of 14C-OPS-2071 Following a Single Oral Dose to Healthy Male Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2016
At a glance
- Drugs OPS 2071 (Primary)
- Indications Bacterial infections; Enteritis
- Focus Pharmacokinetics
- Sponsors Otsuka Pharmaceutical
- 23 Oct 2016 Last checked against ClinicalTrials.gov record.
- 09 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 16 Oct 2015 Planned End Date changed from 1 Jul 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.